Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Caraballo Galva LD, Jiang X, Hussein MS, Zhang H, Mao R, Brody P, Peng Y, He AR, Kehinde-Ige M, Sadek R, Qiu X, Shi H, He Y.
Caraballo Galva LD, et al. Among authors: peng y.
Hepatology. 2022 Aug;76(2):330-344. doi: 10.1002/hep.32279. Epub 2021 Dec 27.
Hepatology. 2022.
PMID: 34897774
Free PMC article.